piracetam has been researched along with Affective Psychosis, Bipolar in 16 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levetiracetam (LEV) is a novel anticonvulsant that is currently investigated in bipolar disorder." | 7.72 | Levetiracetam in the treatment of rapid cycling bipolar disorder. ( Bräunig, P; Krüger, S, 2003) |
| "A 38-year-old woman reportedly ingested 60 (500 mg) tablets of levetiracetam that she used as a mood-stabilizing medication for bipolar disorder." | 7.71 | A case of levetiracetam (Keppra) poisoning with clinical and toxicokinetic data. ( Barrueto, F; Hoffman, RS; Howland, MA; Nelson, LS; Williams, K, 2002) |
| "Levetiracetam is a recently approved, well-tolerated anticonvulsant with a unique mechanism of action yielding efficacy in treatment-refractory seizure disorders and positive effects in an animal model of mania." | 6.71 | Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. ( Altshuler, LL; Frye, MA; Grunze, H; Keck, PE; Kupka, R; Leverich, GS; Luckenbaugh, DA; McElroy, SL; Nolen, WA; Post, RM; Suppes, T; Walden, J, 2005) |
| "Levetiracetam is a novel anticonvulsant with antikindling, inhibitory, and neuroprotective properties that is effective in an animal model of mania." | 5.32 | Monotherapy treatment of bipolar disorder with levetiracetam. ( Kaufman, KR, 2004) |
| "To study the efficacy of adjunctive levetiracetam therapy compared with placebo in the treatment of subjects with depression with bipolar disorder." | 5.15 | Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. ( Bhagwagar, Z; Blumberg, HP; Lorberg, B; Maloney, K; Muralidharan, A; Pittman, B; Ruf, B; Sanacora, G; Saricicek, A, 2011) |
| "Levetiracetam (LEV) is a novel anticonvulsant that is currently investigated in bipolar disorder." | 3.72 | Levetiracetam in the treatment of rapid cycling bipolar disorder. ( Bräunig, P; Krüger, S, 2003) |
| "A 38-year-old woman reportedly ingested 60 (500 mg) tablets of levetiracetam that she used as a mood-stabilizing medication for bipolar disorder." | 3.71 | A case of levetiracetam (Keppra) poisoning with clinical and toxicokinetic data. ( Barrueto, F; Hoffman, RS; Howland, MA; Nelson, LS; Williams, K, 2002) |
| "A study of 246 patients (with schizophrenia, manic depressive psychoses and psychoorganic syndrome) treated by some drugs of a metabolic action (encephalotropic", "nootropic" drugs, piracetam, piriditol and pantogam) permitted one to determine the place of these preparations in a comprehensive treatment of mental disorders." | 3.66 | [Certain principles for differential utilization of metabolic treatment preparations in the complex therapy of mental disorders]. ( Avrutskiĭ, GIa; Laskova, NB, 1979) |
| "Levetiracetam is a novel antiepileptic drug with a broad spectrum of efficacy in epilepsy." | 2.71 | Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. ( Born, C; Grunze, H; Langosch, J; Schaub, G; Walden, J, 2003) |
| "Levetiracetam is a recently approved, well-tolerated anticonvulsant with a unique mechanism of action yielding efficacy in treatment-refractory seizure disorders and positive effects in an animal model of mania." | 2.71 | Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. ( Altshuler, LL; Frye, MA; Grunze, H; Keck, PE; Kupka, R; Leverich, GS; Luckenbaugh, DA; McElroy, SL; Nolen, WA; Post, RM; Suppes, T; Walden, J, 2005) |
| "Levetiracetam is a novel anticonvulsant with antikindling, inhibitory, and neuroprotective properties that is effective in an animal model of mania." | 1.32 | Monotherapy treatment of bipolar disorder with levetiracetam. ( Kaufman, KR, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (75.00) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dubovsky, SL | 1 |
| Daurignac, E | 1 |
| Leonard, KE | 1 |
| Serotte, JC | 1 |
| Saricicek, A | 1 |
| Maloney, K | 1 |
| Muralidharan, A | 1 |
| Ruf, B | 1 |
| Blumberg, HP | 1 |
| Sanacora, G | 1 |
| Lorberg, B | 1 |
| Pittman, B | 1 |
| Bhagwagar, Z | 1 |
| Barrueto, F | 1 |
| Williams, K | 1 |
| Howland, MA | 1 |
| Hoffman, RS | 1 |
| Nelson, LS | 1 |
| Bräunig, P | 2 |
| Krüger, S | 2 |
| Grunze, H | 2 |
| Langosch, J | 1 |
| Born, C | 1 |
| Schaub, G | 1 |
| Walden, J | 2 |
| Yatham, LN | 1 |
| Bersani, G | 1 |
| Kaufman, KR | 1 |
| Post, RM | 1 |
| Altshuler, LL | 1 |
| Frye, MA | 1 |
| Suppes, T | 1 |
| McElroy, SL | 1 |
| Keck, PE | 1 |
| Leverich, GS | 1 |
| Kupka, R | 1 |
| Nolen, WA | 1 |
| Luckenbaugh, DA | 1 |
| Kyomen, HH | 2 |
| Desarkar, P | 1 |
| Das, B | 1 |
| Sinha, VK | 1 |
| Whitfield, TH | 1 |
| Baldessarini, RJ | 1 |
| Sarkar, R | 1 |
| Pietsch, R | 1 |
| Hasenclever, D | 1 |
| Goldberg, JF | 1 |
| Burdick, KE | 1 |
| Avrutskiĭ, GIa | 1 |
| Laskova, NB | 1 |
| Chaturvedi, SK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Levetiracetam in the Management of Bipolar Depression[NCT00566150] | 35 participants (Actual) | Interventional | 2005-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change is observed value at each visit minus baseline value. CGI-BP depression severity is an instrument which measures severity of depression in bipolar disorder. Scale range: 1=normal, not ill; 7=very severely ill (NCT00566150)
Timeframe: Baseline to week 6
| Intervention | score on scale (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Week 1 (n=17, n=15) | Week 2 (n=14, n=14) | Week 3 (n=13, n=14) | Week 4 (n=11, n=13) | Week 5 (n=11, n=12) | Week 6 (n=10, n=10) | |
| Levetiracetam | -0.2941 | -0.3186 | -0.1984 | -0.3729 | -0.7325 | -0.5742 |
| Placebo | -0.4667 | -0.6956 | -0.7753 | -0.8403 | -0.8739 | -0.9294 |
Change is observed value at each visit minus baseline value. HDRS-21 is a 21-item instrument measuring depression. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 60. (NCT00566150)
Timeframe: Baseline to week 6
| Intervention | score on scale (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Week 1 (n=17, n=15) | Week 2 (n=15, n=14) | Week 3 (n=13, n=14) | Week 4 (n=11, n=13) | Week 5 (n=11, n=13) | Week 6 (n=10, n=11) | |
| Levetiracetam | -2.7647 | -3.4259 | -2.1243 | -4.3534 | -6.952 | -4.8136 |
| Placebo | -4 | -6.5875 | -6.3625 | -6.3851 | -6.4368 | -7.0712 |
Change is observed value at each visit minus baseline value. MADRS is a 10-item instrument measuring depression: scale range between 0(normal) - 6(most abnormal)for each item. Total possible score is 0 - 60. (NCT00566150)
Timeframe: Baseline to week 6
| Intervention | score on scale (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Week 1 (n=17, n=15) | Week 2 (n=15, n=14) | Week 3 (n=13, n=14) | Week 4 (n=11, n=13) | Week 5 (n=11, n=12) | Week 6 (n=10, n=11) | |
| Levetiracetam | -3.2941 | -5.2319 | -3.384 | -5.5505 | -9.9142 | -6.5208 |
| Placebo | -2.7333 | -7.256 | -9.0417 | -8.7608 | -6.6591 | -4.5153 |
"Remission response is measured as an HDRS-21 total score is less than or equal to 7.~HDRS-21 measures range of depressive symptoms. Endpoint is LOCF." (NCT00566150)
Timeframe: Week 6
| Intervention | Participants (Number) | |
|---|---|---|
| Remitted | Not remitted | |
| Levetiracetam | 0 | 17 |
| Placebo | 4 | 11 |
1 review available for piracetam and Affective Psychosis, Bipolar
| Article | Year |
|---|---|
Newer anticonvulsants in the treatment of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Dep | 2004 |
6 trials available for piracetam and Affective Psychosis, Bipolar
| Article | Year |
|---|---|
Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Double-Blind Method; Female; Humans; Levetiracetam; | 2011 |
Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design.
Topics: Acute Disease; Adult; Anticonvulsants; Bipolar Disorder; Diagnostic and Statistical Manual of Mental | 2003 |
Levetiracetam in bipolar spectrum disorders: first evidence of efficacy in an open, add- on study.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Therapy, Combination | 2004 |
Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder.
Topics: Adult; Ambulatory Care; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Combi | 2005 |
Levetiracetam for manic behavior in hospitalized geriatric patients with dementia of the Alzheimer's type.
Topics: Aged; Alzheimer Disease; Bipolar Disorder; Female; Humans; Levetiracetam; Male; Nootropic Agents; Pi | 2007 |
Levetiracetam as monotherapy or add-on to valproate in the treatment of acute mania-a randomized open-label study.
Topics: Anticonvulsants; Bipolar Disorder; Drug Therapy, Combination; Humans; Levetiracetam; Piracetam; Psyc | 2008 |
9 other studies available for piracetam and Affective Psychosis, Bipolar
| Article | Year |
|---|---|
Levetiracetam, Calcium Antagonism, and Bipolar Disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Calcium; Calcium Channel Blockers; Female; Humans; Levetir | 2015 |
A case of levetiracetam (Keppra) poisoning with clinical and toxicokinetic data.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Drug Overdose; Female; Half-Life; Humans; Levetiracetam; N | 2002 |
Levetiracetam in the treatment of rapid cycling bipolar disorder.
Topics: Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; Female; Humans | 2003 |
Monotherapy treatment of bipolar disorder with levetiracetam.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Female; Humans; Levetiracetam; MEDLINE; Piracetam; Review | 2004 |
The use of levetiracetam to decrease mania in elderly bipolar patients.
Topics: Aged; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Ad | 2006 |
Adjuvant levetiracetam in adolescent mania.
Topics: Acute Disease; Adolescent; Anticonvulsants; Bipolar Disorder; Dose-Response Relationship, Drug; Fema | 2007 |
Levetiracetam for acute mania.
Topics: Acute Disease; Adult; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Administration Schedu | 2002 |
[Certain principles for differential utilization of metabolic treatment preparations in the complex therapy of mental disorders].
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Brain Injuries; gamma-Aminobutyric Acid; Humans; Infectio | 1979 |
Piracetam for drug-induced dyskinesia.
Topics: Adult; Bipolar Disorder; Chlorpromazine; Dyskinesia, Drug-Induced; Female; Humans; Piracetam; Pyrrol | 1987 |